市場調查報告書
商品編碼
879149

甲狀腺未分化癌症治療藥 - 全球市場預測(2017年∼2026年)

Anaplastic Thyroid Cancer Drugs - Global Market Outlook (2017-2026)

出版日期: | 出版商: Stratistics Market Research Consulting | 英文 164 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球甲狀腺未分化癌症治療藥市場在2017年估算為1億3,956萬美元,至2026年預計將以5.8%的年複合成長率發展,至2026年成長到2億3,181萬美元。預計化療的償付制度等促進這個市場成長。可是,預計治療藥高額將阻礙成長。

本報告提供全球甲狀腺未分化癌症治療藥市場調查,市場概要,各類型、產品、治療方法、給藥途徑、用途、地區的市場規模的變化與預測,市場成長要素及阻礙因素分析,市場機會,競爭情形,主要企業的簡介等全面性資訊。

目錄

第1章 摘要整理

第2章 簡介

第3章 市場趨勢分析

  • 簡介
  • 成長要素
  • 阻礙因素
  • 市場機會
  • 威脅
  • 產品分析
  • 用途分析
  • 新興市場
  • 今後的市場情況

第4章 波特的五力分析

  • 買方議價能力
  • 供給企業談判力
  • 新加入業者的威脅
  • 替代品的威脅
  • 競爭企業間的敵對關係

第5章 全球甲狀腺未分化癌症治療藥市場:各類型

  • 簡介
  • Crolibulin
  • Efatutazone
  • GLONC-2
  • CLM-94
  • 其他

第6章 全球甲狀腺未分化癌症治療藥市場:各產品

  • 簡介
  • Sorafenib(第二階段)
  • Paclitaxel、Pazopanib HCl(第二階段)
  • MLN0128(第二階段)
  • Lapatinib Ditosylate、Dabrafenib(第一階段)
  • Everolimus(第二階段)
  • CS7017(第一階段)
  • Crolibulin(第一階段)
  • Cabozantinib(第二階段)
  • CA4P(第二階段)
  • Bevacizumab(第二階段)
  • 其他商品

第7章 全球甲狀腺未分化癌症治療藥市場:各治療法

  • 簡介
  • 外科的治療
  • 放射線治療
  • 新治療方法
  • 冷凍治療
  • 化療

第8章 全球甲狀腺未分化癌症治療藥市場:各給藥途徑

  • 簡介
  • 口服
  • 注射

第9章 全球甲狀腺未分化癌症治療藥市場:各用途

  • 簡介
  • 診療所
  • 醫院
  • 其他的用途

第10章 全球甲狀腺未分化癌症治療藥市場:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他
  • 南美
    • 阿根廷
    • 巴西
    • 智利
    • 其他
  • 中東、非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他

第11章 市場主要趨勢

  • 契約、夥伴關係、合作、合資企業
  • 收購、合併
  • 新產品的銷售
  • 事業擴張
  • 其他主要策略

第12章 企業簡介

  • Pfizer Inc.
  • 第一三共
  • Trophogen, Inc.
  • Plexxikon Inc.
  • Novartis AG
  • Millennium Pharmaceuticals Inc
  • Immune Pharmaceuticals Inc.
  • Genelux Corporation
目錄

According to Stratistics MRC, the Global Anaplastic Thyroid Cancer Drugs market is accounted for $ 139.56 million in 2017 and is expected to reach $ 231.81 million by 2026 growing at a CAGR of 5.8% during the forecast period. Some of the key factors such as the existence of recompense policy for chemotherapy will include a useful blow which is propelling the growth of the market. However, the charge of this therapeutics is exceptionally high which is hampering the growth of the market.

Anaplastic Thyroid Cancer is the mainly exceptional thyroid cancer, in the main lethal thyroid cancer, and the main complex thyroid cancer to do surgery upon. The accurate operation depends upon the anaplastic thyroid cancer scope of the attack and is merely even measured suitable while there is extremely no proof that there is any remote spread of the infection. The entire anaplastic thyroid cancer is isolated from the neck in the early surgery. imperfect surgery is not correctable.

Based on the treatments available, Chemotherapy is universal treatment, which means that the medicine enters the blood torrent and travels all over the body to arrive at and demolish cancer cells. The Chemotherapy uses anti-cancer drugs to be injected into a layer or engaged by mouth. It is frequently joint with exterior beam radiation therapy for anaplastic thyroid cancer and is occasionally used for other higher cancers that no longer react to other treatments.

By Geography, North America was the maximum returns provider to the global anaplastic thyroid cancer drugs market. It will retain its top place during the forecast period. Anaplastic thyroid cancer is ordinary with adult citizens. Thus, the growing aged population in the region is most important to market growth. Furthermore, the rising quantity of awareness programs, being conducted by vendors and healthcare organizations, are also bolstering the growth of the anaplastic thyroid cancer drugs market in North America.

Some of the key players profiled in the Anaplastic Thyroid Cancer Drugs Market include Pfizer Inc., Daiichi Sankyo Company, Limited, Trophogen, Inc., Plexxikon Inc., Novartis Ag, Millennium Pharmaceuticals Inc, Immune Pharmaceuticals Inc., and Genelux Corporation.

Types Covered:

  • Crolibulin
  • Efatutazone
  • GLONC-2
  • CLM-94
  • Other Types

Products Covered:

  • Sorafenib (phase 2)
  • Paclitaxel and Pazopanib HCl (phase 2)
  • MLN0128 (phase 2)
  • Lapatinib Ditosylate and Dabrafenib (phase 1)
  • Everolimus (phase 2)
  • CS7017 (phase 1)
  • Crolibulin (phase 1)
  • Cabozantinib (phase 2)
  • CA4P (phase 2)
  • Bevacizumab (phase 2)
  • Other Products

Treatments Covered:

  • Surgical Treatments
  • Radiation Therapy
  • Novel Therapy
  • Cryosurgery
  • Chemotherapy

Methods Covered:

  • Oral
  • Injection

Applications Covered:

  • Clinic
  • Hospital
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country level segments
  • Market share analysis of the top industry players
  • Strategic recommendations for the new entrants
  • Market forecasts for a minimum of 9 years of all the mentioned segments, sub-segments, and the regional markets
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check)
  • Competitive Benchmarking

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Futuristic Market Scenario

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Anaplastic Thyroid Cancer Drugs Market, By Type

  • 5.1 Introduction
  • 5.2 Crolibulin
  • 5.3 Efatutazone
  • 5.4 GLONC-2
  • 5.5 CLM-94
  • 5.6 Other Types

6 Global Anaplastic Thyroid Cancer Drugs Market, By Product

  • 6.1 Introduction
  • 6.2 Sorafenib (phase 2)
  • 6.3 Paclitaxel and Pazopanib HCl (phase 2)
  • 6.4 MLN0128 (phase 2)
  • 6.5 Lapatinib Ditosylate and Dabrafenib (phase 1)
  • 6.6 Everolimus (phase 2)
  • 6.7 CS7017 (phase 1)
  • 6.8 Crolibulin (phase 1)
  • 6.9 Cabozantinib (phase 2)
  • 6.10 CA4P (phase 2)
  • 6.11 Bevacizumab (phase 2)
  • 6.12 Other Products

7 Global Anaplastic Thyroid Cancer Drugs Market, By Treatments

  • 7.1 Introduction
  • 7.2 Surgical Treatments
  • 7.3 Radiation Therapy
  • 7.4 Novel Therapy
  • 7.5 Cryosurgery
  • 7.6 Chemotherapy

8 Global Anaplastic Thyroid Cancer Drugs Market, By Method

  • 8.1 Introduction
  • 8.2 Oral
  • 8.3 Injection

9 Global Anaplastic Thyroid Cancer Drugs Market, By Application

  • 9.1 Introduction
  • 9.2 Clinic
  • 9.3 Hospital
  • 9.4 Other Applications

10 Global Anaplastic Thyroid Cancer Drugs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.6 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Pfizer Inc.
  • 12.2 Daiichi Sankyo Company, Limited
  • 12.3 Trophogen, Inc.
  • 12.4 Plexxikon Inc.
  • 12.5 Novartis AG
  • 12.6 Millennium Pharmaceuticals Inc
  • 12.7 Immune Pharmaceuticals Inc.
  • 12.8 Genelux Corporation

List of Tables

  • Table 1 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Region (2016-2026) (US $MN)
  • Table 2 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Type (2016-2026) (US $MN)
  • Table 3 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Crolibulin (2016-2026) (US $MN)
  • Table 4 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Efatutazone (2016-2026) (US $MN)
  • Table 5 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By GLONC-2 (2016-2026) (US $MN)
  • Table 6 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By CLM-94 (2016-2026) (US $MN)
  • Table 7 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Other Types (2016-2026) (US $MN)
  • Table 8 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Product (2016-2026) (US $MN)
  • Table 9 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Sorafenib (phase 2) (2016-2026) (US $MN)
  • Table 10 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Paclitaxel and Pazopanib HCl (phase 2) (2016-2026) (US $MN)
  • Table 11 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By MLN0128 (phase 2) (2016-2026) (US $MN)
  • Table 12 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Lapatinib Ditosylate and Dabrafenib (phase 1) (2016-2026) (US $MN)
  • Table 13 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Everolimus (phase 2) (2016-2026) (US $MN)
  • Table 14 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By CS7017 (phase 1) (2016-2026) (US $MN)
  • Table 15 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Crolibulin (phase 1) (2016-2026) (US $MN)
  • Table 16 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Cabozantinib (phase 2) (2016-2026) (US $MN)
  • Table 17 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By CA4P (phase 2) (2016-2026) (US $MN)
  • Table 18 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Bevacizumab (phase 2) (2016-2026) (US $MN)
  • Table 19 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Other Products (2016-2026) (US $MN)
  • Table 20 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Treatments (2016-2026) (US $MN)
  • Table 21 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Surgical Treatments (2016-2026) (US $MN)
  • Table 22 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Radiation Therapy (2016-2026) (US $MN)
  • Table 23 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Novel Therapy (2016-2026) (US $MN)
  • Table 24 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Cryosurgery (2016-2026) (US $MN)
  • Table 25 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Chemotherapy (2016-2026) (US $MN)
  • Table 26 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Method (2016-2026) (US $MN)
  • Table 27 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Oral (2016-2026) (US $MN)
  • Table 28 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Injection (2016-2026) (US $MN)
  • Table 29 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Application (2016-2026) (US $MN)
  • Table 30 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Clinic (2016-2026) (US $MN)
  • Table 31 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Hospital (2016-2026) (US $MN)
  • Table 32 Global Anaplastic Thyroid Cancer Drugs Market Outlook, By Other Applications (2016-2026) (US $MN)

NOTE: Tables for North America, Europe, Asia Pacific, South America, and Middle East & Africa are represented in the same manner above.